Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-05-01 (bloomberg.com)
Biogen Lowers Profit Outlook After Deal for Epilepsy Drug
cut its profit guidance for the year to reflect the cost to acquire the rights to a genetic seizure disorder drug.
Read more
2025-03-24 (marketbeat.com)
Hillsdale Investment Management Inc. Acquires New Holdings in Biogen Inc. (NASDAQ:BIIB)
Hillsdale Investment Management Inc. acquired a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,610 shares of the biotechnology company's stock, valued at approximat
Read more
2022-09-29 (e-fundresearch.com)
Lumyna - American Debt - Credit UCITS Fund
Fund Rankings & Insights - Lumyna American Dbt Crdt UCITS USD B Inc (LU2479960952) - Lumyna Investments Limited - other bond funds and global corporate bonds (USD-hedged) funds in the fund ranking on e-fundresearch.com
Read more
2021-08-16 (reuters.com)
Buffett's Berkshire pares drug holdings, sheds Axalta, Biogen |
Warren Buffett's Berkshire Hathaway Inc (BRKa.N) said on Monday it trimmed or eliminated its stakes in several pharmaceutical companies, and reported a small new stake in a Merck & Co (MRK.N) spinoff, Organon & Co (OGN.N).
Read more